You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
NameDarbepoetin alfa
Accession NumberDB00012  (BIOD00032, BTD00032)
GroupsApproved, Investigational

Human erythropoietin with 2 aa substitutions to enhance glycosylation (5 N-linked chains), 165 residues (MW=37 kD). Produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.

Protein structureDb00012
Protein chemical formulaC815H1317N233O241S5
Protein average weight18396.1000
>DB00012 sequence
Download FASTA Format
EpoetinNot AvailableNot Available
Erythropoietin precursorNot AvailableNot Available
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Aranespsolution25 ug/mLintravenous; subcutaneousAmgen Inc2006-09-11Not AvailableUs
Aranespsolution40 ug/mLintravenous; subcutaneousAmgen Inc2006-09-11Not AvailableUs
Aranespsolution60 ug/mLintravenous; subcutaneousAmgen Inc2006-09-11Not AvailableUs
Aranespsolution100 ug/mLintravenous; subcutaneousAmgen Inc2006-09-11Not AvailableUs
Aranespsolution200 ug/mLintravenous; subcutaneousAmgen Inc2006-09-11Not AvailableUs
Aranespinjection, solution40 ug/.4mLintravenous; subcutaneousAmgen Inc2006-08-14Not AvailableUs
Aranespinjection, solution60 ug/.3mLintravenous; subcutaneousAmgen Inc2006-08-14Not AvailableUs
Aranespinjection, solution100 ug/.5mLintravenous; subcutaneousAmgen Inc2006-08-14Not AvailableUs
Aranespinjection, solution150 ug/.3mLintravenous; subcutaneousAmgen Inc2006-09-11Not AvailableUs
Aranespinjection, solution200 ug/.4mLintravenous; subcutaneousAmgen Inc2006-08-14Not AvailableUs
Aranespinjection, solution500 ug/mLintravenous; subcutaneousAmgen Inc2006-06-07Not AvailableUs
Aranespsolution150 ug/.75mLintravenous; subcutaneousAmgen Inc2006-09-11Not AvailableUs
Aranespinjection, solution25 ug/.42mLintravenous; subcutaneousAmgen Inc2006-08-26Not AvailableUs
Aranespsolution300 ug/mLintravenous; subcutaneousAmgen Inc2006-08-14Not AvailableUs
Aranespinjection, solution300 ug/.6mLintravenous; subcutaneousAmgen Inc2006-08-14Not AvailableUs
Generic Prescription ProductsNot Available
Over the Counter ProductsNot Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
CAS number11096-26-7
DescriptionNot Available
KingdomOrganic Compounds
Super ClassOrganic Acids
ClassCarboxylic Acids and Derivatives
Sub ClassAmino Acids, Peptides, and Analogues
Direct ParentPeptides
Alternative ParentsNot Available
SubstituentsNot Available
Molecular FrameworkNot Available
External DescriptorsNot Available
IndicationFor the treatment of anemia (from renal transplants or certain HIV treatment)
PharmacodynamicsDarbepoetin alfa is used in the treatment of anemia. It is involved in the regulation of erythrocyte differentiation and the maintenance of a physiological level of circulating erythrocyte mass.
Mechanism of actionDarbepoetin alfa stimulates erythropoiesis by the same mechanism as endogenous erythropoietin. Erythropoietin interacts with progenitor stem cells to increase red cell production. Binding of erythropoietin to the erythropoietin receptor leads to receptor dimerization, which facilitates activation of JAK-STAT signaling pathways within the cytosol. Activated STAT (signal transducers and activators of transcription) proteins are then translocated to the nucleus where they serve as transcription factors which regulate the activation of specific genes involved in cell division or differentiation.
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
  • Amgen Inc.
Dosage forms
Injection, solutionintravenous; subcutaneous100 ug/.5mL
Injection, solutionintravenous; subcutaneous150 ug/.3mL
Injection, solutionintravenous; subcutaneous200 ug/.4mL
Injection, solutionintravenous; subcutaneous25 ug/.42mL
Injection, solutionintravenous; subcutaneous300 ug/.6mL
Injection, solutionintravenous; subcutaneous40 ug/.4mL
Injection, solutionintravenous; subcutaneous500 ug/mL
Injection, solutionintravenous; subcutaneous60 ug/.3mL
Solutionintravenous; subcutaneous100 ug/mL
Solutionintravenous; subcutaneous150 ug/.75mL
Solutionintravenous; subcutaneous200 ug/mL
Solutionintravenous; subcutaneous25 ug/mL
Solutionintravenous; subcutaneous300 ug/mL
Solutionintravenous; subcutaneous40 ug/mL
Solutionintravenous; subcutaneous60 ug/mL
Unit descriptionCostUnit
Aranesp (Albumin Free) 150 mcg/0.75ml Solution (1 Box = Four 0.75ml Vials)3902.75USD box
Aranesp (Albumin Free) 100 mcg/0.5ml Solution (1 Box = Four 0.5ml Syringes)2601.83USD box
Aranesp (Albumin Free) 100 mcg/ml Solution Four 1ml Vials Per Box2601.83USD box
Aranesp (Albumin Free) 300 mcg/ml vial1951.37USD vial
Aranesp 300 mcg/ml vial1876.32USD ml
Aranesp 200 mcg/ml vial1250.88USD ml
Aranesp 100 mcg/ml vial625.44USD ml
Aranesp (Albumin Free) 60 mcg/ml vial390.31USD vial
Aranesp 60 mcg/ml vial375.3USD ml
Aranesp 40 mcg/ml vial250.2USD ml
Aranesp (Albumin Free) 25 mcg/ml vial162.61USD vial
Aranesp 25 mcg/ml vial156.36USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
CountryPatent NumberApprovedExpires (estimated)
Experimental Properties
melting point53 °CArakawa, T. et al., Biosci. Biotechnol. Biochem. 65:1321-1327 (2001)
hydrophobicity-0.188Not Available
isoelectric point8.75Not Available
Synthesis ReferenceNot Available
General ReferenceNot Available
External Links
ATC CodesB03XA02
AHFS Codes
  • 20:16.00
PDB Entries
FDA labelNot Available
MSDSNot Available
Drug InteractionsSearched, but no interactions found.
Food InteractionsNot Available


1. Erythropoietin receptor

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: agonist


Name UniProt ID Details
Erythropoietin receptor P19235 Details


  1. LaMontagne KR, Butler J, Marshall DJ, Tullai J, Gechtman Z, Hall C, Meshaw A, Farrell FX: Recombinant epoetins do not stimulate tumor growth in erythropoietin receptor-positive breast carcinoma models. Mol Cancer Ther. 2006 Feb;5(2):347-55. Pubmed
  2. Kokhaei P, Abdalla AO, Hansson L, Mikaelsson E, Kubbies M, Haselbeck A, Jernberg-Wiklund H, Mellstedt H, Osterborg A: Expression of erythropoietin receptor and in vitro functional effects of epoetins in B-cell malignancies. Clin Cancer Res. 2007 Jun 15;13(12):3536-44. Pubmed
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed

comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 03, 2011 16:35